MATERA, Maria Gabriella
 Distribuzione geografica
Continente #
EU - Europa 6.184
NA - Nord America 5.240
AS - Asia 529
SA - Sud America 17
Continente sconosciuto - Info sul continente non disponibili 11
AF - Africa 7
OC - Oceania 7
Totale 11.995
Nazione #
US - Stati Uniti d'America 5.223
IE - Irlanda 1.955
UA - Ucraina 1.110
GB - Regno Unito 821
DE - Germania 670
IT - Italia 633
CN - Cina 295
FI - Finlandia 267
FR - Francia 239
GR - Grecia 221
SE - Svezia 187
TR - Turchia 156
BE - Belgio 22
ID - Indonesia 17
CA - Canada 13
ES - Italia 13
JP - Giappone 10
NL - Olanda 10
KR - Corea 9
CL - Cile 8
EU - Europa 8
IR - Iran 8
IL - Israele 7
IN - India 7
MD - Moldavia 7
AU - Australia 6
PE - Perù 6
PL - Polonia 6
TW - Taiwan 6
CZ - Repubblica Ceca 4
RU - Federazione Russa 4
SG - Singapore 4
AT - Austria 3
CH - Svizzera 3
AP - ???statistics.table.value.countryCode.AP??? 2
BR - Brasile 2
HK - Hong Kong 2
MA - Marocco 2
MX - Messico 2
SA - Arabia Saudita 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BB - Barbados 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
CO - Colombia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
HR - Croazia 1
HU - Ungheria 1
IM - Isola di Man 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UZ - Uzbekistan 1
VN - Vietnam 1
Totale 11.995
Città #
Dublin 1.953
Jacksonville 1.714
Chandler 756
Princeton 359
Medford 326
Bremen 225
Roxbury 188
Boardman 161
San Mateo 158
Wilmington 139
Ann Arbor 102
Woodbridge 86
Beijing 81
Cambridge 77
Des Moines 70
Düsseldorf 49
Ashburn 43
Caserta 42
New York 33
Norwalk 31
Jinan 29
Naples 27
Brussels 21
Rome 19
Hebei 18
Napoli 18
Shanghai 18
Mountain View 16
Zhengzhou 16
Los Angeles 15
Nanjing 15
Redwood City 15
Shenyang 14
Auburn Hills 12
Houston 12
Dearborn 11
Haikou 11
Changsha 9
Casoria 8
Hangzhou 8
Hefei 8
Padang 8
Strasbourg 8
Bologna 7
Chisinau 7
Lanzhou 7
London 7
Monza 7
Salerno 7
Venice 7
Bari 6
Giv‘atayim 6
Groningen 6
Hanover 6
Lima 6
Marano Di Napoli 6
Nanchang 6
Ningbo 6
Scafati 6
Seattle 6
Seoul 6
Taiyuan 6
Avellino 5
Milan 5
Taipei 5
Barcelona 4
Fairfield 4
Hamilton 4
Menlo Park 4
Padula 4
Piedimonte 4
Portici 4
Taizhou 4
Tianjin 4
Tolentino 4
Akita 3
Benevento 3
Biella 3
Cagliari 3
Florence 3
Giugliano In Campania 3
Grafing 3
Guangzhou 3
Gunzenhausen 3
Hengyang 3
Lauro 3
Marcianise 3
Mascalucia 3
Munich 3
Nuremberg 3
Ottaviano 3
Pontedera 3
Santa Maria a Vico 3
Shenzhen 3
Stella Cilento 3
Toronto 3
Turin 3
Ulez 3
Andover 2
Atlanta 2
Totale 7.178
Nome #
Farmaci dell’Apparato Respiratorio: Regolazione del tono broncomotore. 321
Sistema purinergico. 235
“COPDCoRi: applicazione non invasiva per la stima e la previsione del rischio di patologia coronarica nei pazienti affetti da broncopneumopatia cronica ostruttiva (BPCO)”. 89
Antiflammins suppress the A23187- and arachidonic acid-dependent chloride secretion in rabbit distal colonic mucosa 88
Effects of chronic administration of β-blockers on airway responsiveness in a murine model of heart failure. 70
Evidence of muscarinic receptor subtypes in airway smooth muscle of normal volunteers and of chronic obstructive pulmonary disease patients 64
Excitatory amino acids and cardiovascular apparatus: experimental studies on conscious rats with L-glutamate, N-methyl-D-aspartate, kainate and quisqualate 63
Flomoxef, a new oxacephem antibiotic, does not cause hemostatic defects 63
Pulmonary penetration of dirithromycin in patients suffering from acute exacerbation of chronic bronchitis 62
Intraulmonary penetration of antimicrobials and implications in the treatment of lower respiratory tract infections. 62
Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. 61
Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. 60
Prenatal and postnatal vanadium exposure in rats: effect on vasomotor reactivity development of pups 60
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. 59
Effects of hyperbaric oxygen exposure on non-adrenergic non-cholinergic responses of rat trachea 59
A comparison of sensory nerve function in human, guinea-pig, rabbit and marmoset airways 59
10. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. 59
Treatment of COPD: moving beyond the lungs. 59
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. 58
Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling. 57
Terapie per i disordini labirintici: effetti e riflessi sulla pressione arteriosa 56
Amminoacidi eccitatori e regolazione centrale della funzione cardiovascolare: contributi sperimentali. 56
The anti-proliferative effects of adiponectin on human lung adenocarcinoma A549 cells and oxidative stress involvement 56
The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study 55
Ions and intracellular mechanisms involved in the effects of L-glutamate on arginine vasopressin release: in vitro researches on rat neurohypophysis 55
Effects of in vitro 5-HT1 receptor activation in guinea pig trachea 55
Bioavailability of timolol and aceclidine after ocular instillation in the rabbit 55
A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease 55
Farmaci per il trattamento delle aritmie cardiache. 55
Brain natriuretic peptide : much more than a biomarker 55
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis 55
Protein Prenylation Contributes to the Effects of LPS on EFS-Induced Responses in Human Isolated Bronchi 54
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. 53
1. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. 53
characterization of the Pharmacological interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. 52
Characterization of adenosine receptors involved in adenosine-induced bronchoconstriction in allergic rabbits 52
Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD. 51
Evidence for non-adrenergic non-cholinergic contractile responses in bovine and swine trachea 51
Calcium dependence of the evoked arginine vasopressin release by electrical stimulation and by L-glutamate 50
A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease 50
Research on heterocyclic compounds. XIV - Imidazothiazole and imidazobenzothiazole derivatives: synthesis and antiinflammatory activity 50
Possible functional modulation by acetylcholine of nitric oxide on guinea pig isolated trachea 50
Nitric oxide regulatory role in sensitized guinea pig trachea 50
Assessing the viability of long-acting β(2)-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective. 50
Pharmacological Characterization of Adenosine Receptors on Isolated Human Bronchi 49
Brain Natriuretic Peptide Protects Against Hyperreactivity of Human Asthmatic Airway Smooth Muscle via an Epithelial Cell Dependent Mechanism. 49
Prenatal and postnatal antimony exposure in rats: effect on vasomotor reactivity development of pups 49
K+ channels and guinea-pig trachea: a possible functional modulation by GABAB receptors 49
A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD 49
Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema 49
Treating systemic effects of COPD. 48
Role of 5-hydroxytryptamine in mediating adenosine-induced airway contraction 48
Role of 5-HT2 receptor subtypes in mediating adenosine-induced airway contraction 48
Teicoplanin with other drugs: possible pharmacological interactions 48
Farmaci per il trattamento della cardiopatia ischemica. 48
I farmaci dell'apparato gastrointestinale 48
Pulmonary concentrations of dirithromycin and erythromycin during acute exacerbation of mild chronic obstructive pulmonary disease 47
Serum digoxin levels after concomitant ticarcillin and clavulanic acid administration 47
Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. 47
Effect of hyperbaric oxygen therapy in experimental subcutaneous and pulmonary infections due to Pseudomonas aeruginosa 47
I farmaci del sistema nervoso centrale 47
Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple therapy in COPD 47
LABAs in asthmatic children: highlights and new inside. 46
N-acetylcysteine in COPD may be beneficial, but for whom? 46
Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. 46
Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter? 46
Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler 45
Theophylline in the inhibition of angiotensin-converting enzyme inhibitor-induced cough 45
Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination 45
A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease 45
Effect of telenzepine, an M1-selective muscarinic receptor antagonist, in patients with nocturnal asthma 44
Effects of RO 5-4864 and PK 11195 on guinea pig trachea 44
Long-acting bronchodilators are the first-choice option for the treatment of stable COPD 44
Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study 44
Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi 44
Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease 43
Pulmonary disposition of lomefloxacin in patients with acute exacerbation of chronic obstructive pulmonary disease. A multiple-dose study 43
Treatment of Chronic Obstructive Pulmonary Disease by Dual Bronchodilation with Coformulation of Indacaterol/Glycopyrronium. 43
Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. 43
Adenosine receptors: novel targets for drug development in allergic rhinitis 43
Farmaci per il trattamento dello scompenso cardiaco. 43
Fixed-Dose Combination Inhalers 43
Functional role of nitric oxide in guinea pig tracheal epithelium 42
Addition of an extra dose of salmeterol Diskus to conventional dose of salmeterol Diskus in patients with COPD 42
Fumo passivo ed infezioni batteriche a carico del tratto respiratorio inferiore 42
Evaluation of adiponectin profile in Italian patients affected by obstructive sleep apnea syndrome 42
Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. 42
. Brain natriuretic peptide modulates calcium homeostasis and epidermal growth factor receptor gene signalling in asthmatic airways smooth muscle cells. 41
β(2) -adrenoceptor agonists: current and future direction 41
Clinical pharmacokinetics of salmeterol 41
Sviluppo e uso dei farmaci. 41
Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. 41
Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus 41
Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children 40
Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease 40
Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents 40
Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction 40
I farmaci dell’apparato gastroenterico 40
Farmaci del sistema cardiovascolare, del sangue e del rene 40
Impact of doxofylline in COPD: A pairwise meta-analysis 40
Totale 5.467
Categoria #
all - tutte 49.747
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.747


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201962 0 0 0 0 0 0 0 0 0 0 46 16
2019/20201.737 336 295 35 21 284 40 356 103 142 60 40 25
2020/20212.310 256 7 292 78 387 29 346 282 20 290 261 62
2021/20221.935 168 15 27 42 688 7 25 47 59 70 185 602
2022/20233.445 411 47 36 234 440 248 7 178 1.694 17 53 80
2023/20241.027 103 34 35 138 551 59 36 33 14 21 3 0
Totale 12.344